Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times

Abstract Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. Howe ver, several cases of pregnant women being treated with rituximab are reported herein; an exception is often made in cases with grave illness. We describe an exceptional case of a woman with non-Hodgkin lymphoma of the mucosa-associated lymphoid tissue type where rituximab was given as a single agent without interruption during two consecutive pregnancies. This case can certainly supply important indications on the safety of rituximab.

[1]  F. Passamonti,et al.  Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. , 2018, The oncologist.

[2]  M. Beaulieu,et al.  Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report , 2018, BMC Nephrology.

[3]  S. Hauser,et al.  Rituximab before and during pregnancy , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[4]  A. Sica,et al.  Absence of occult HCV infection in patients experiencing an immunodepression condition. , 2013, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[5]  R. González-Amaro,et al.  Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. , 2013, Rheumatology.

[6]  A. Sica,et al.  Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma , 2013, Infection.

[7]  A. Sica,et al.  Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases , 2011, Hepatology.

[8]  E. Chakravarty,et al.  Pregnancy outcomes after maternal exposure to rituximab. , 2011, Blood.

[9]  J. Dansereau,et al.  Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. , 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[10]  M. Čolović,et al.  Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma , 2009, Archives of Dermatological Research.

[11]  G. T. V. van Well,et al.  Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development , 2008, Clinical & developmental immunology.

[12]  A. Sica,et al.  Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.